Precision medicine advances in breast cancer and Alzheimer's diagnosis

Advancements in precision medicine are transforming the diagnosis and treatment of breast cancer and Alzheimer's disease through molecular analysis and biomarker identification.

In breast cancer care, genomic testing allows clinicians to analyze tumor gene activity to estimate recurrence risks. This helps determine if chemotherapy is necessary for specific patients, potentially avoiding treatments that offer no significant benefit. Additionally, identifying hereditary variants like BRCA1 and BRCA2, as well as biomarkers such as the HER2 protein, enables personalized prevention and targeted therapies. Emerging tools like liquid biopsies, which detect tumor DNA in the blood, are also being developed to provide critical clinical information.

Regarding Alzheimer's disease, laboratory medicine is shifting the diagnostic paradigm from symptom-based identification to biological confirmation. By analyzing biomarkers in blood or cerebrospinal fluid—specifically the accumulation of beta-amyloid and changes in tau protein—medical professionals can detect the disease in its early stages, often before clinical symptoms become evident. These molecular diagnostics are essential for the effective application of new anti-amyloid therapies designed to slow disease progression.